References
- World Health Organization. Fact Sheet (Cancer) No. 297 Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
- American Cancer Society. Global Cancer Facts and Figures 2007. Available at http://www.cancer.org
- Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006;49:3033–44.
- Bellina F, Cauteruccio S, Monti S, Rossi R. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg Med Chem Lett 2006;16:5757–62.
- Ji Y, Tian R, Lin W. QSAR and molecular docking study of a series of combretastatin analogues tubulin inhibitors. LNCS 2007;4689:436.
- Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,49-trimethoxystilbene. Mol Pharmacol 2005;67:1451–9.
- Cao TM, Durrant D, Tripathi A, Liu J, Tsai S, Kellogg GE, Simoni D, Lee RM. Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity. Am J Hematol 2008;83:390–7.
- Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimer by electron crystallography. Nature 1998;391:199–203.
- Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev 2004;4:253–65.
- Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259–96.
- Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 2003;46:3546–54.
- Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin like domain. Nature 2004;428:198–202.
- Jones G, Willett P, Glen RC, Leach AR, Taylor RJ. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48.
- Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005;48:6107–16.
- Kellogg GE, Abraham DJ. Hydrophobicity: is LogP(o/w) more than the sum of its parts? Eur J Med Chem 2000;35:651–61.
- Cozzini P, Fornabaio M, Marabotti A, Abraham DJ, Kellogg GE, Mozzarelli A. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water. J Med Chem 2002;45:2469–83.
- Spyrakis F, Amadasi A, Fornabaio, M, Abraham DJ, Mozzarelli A, Kellogg GE, Cozzini P. The consequences of scoring docked ligand conformations using free energy correlations. Eur J Med Chem 2007;42:921–33.
- Durrant DE, Richards J, Tripathi A, Kellogg GE, Marchetti P, Eleopra M, Grisolia G, Simoni D, Lee RM. Development of water soluble derivatives of cis-3,49,5-trimethoxy-39-aminostilbene for optimization and use in cancer therapy. Invest New Drugs 2009;27:41–52.
- Tripathi A, Fornabio M, Kellogg GE, Gupton JT, Gewirtz DA, Mooberry SL. Docking and hydropathic scoring of polysubstituted pyrroles compounds with anti-tubulin activity. Bioorg Med Chem 2008;16:2235–42.